MedTrace Logo

Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

NCT02073838 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-09-29

No results posted yet for this study

Summary

This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in combination with decitabine.

Conditions

Interventions

DRUG

Ribavirin

DRUG

Vismodegib

DRUG

Decitabine

Sponsors & Collaborators

  • Sarit Assouline

    lead OTHER

Principal Investigators

  • Sarit Assouline, MD · Jewish General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02073838 on ClinicalTrials.gov